Abcam to Report Interim Results on Monday, March 8, 2021

CAMBRIDGE, United Kingdom, Feb. 26, 2021 (GLOBE NEWSWIRE) -- Abcam plc (AIM: ABC; Nasdaq: ABCM) (“Abcam” or the “Company”), a global leader in the supply of life science research tools, will report its Interim Results for the six-month period ended 31 December 2020 at 12.00 p.m. GMT (7.00 a.m. EST) on Monday, March 8, 2021.

Following the announcement, the Company will host a live teleconference and webcast at 2:00 p.m. GMT (9:00 a.m. EST) that same day (details below).

To access the webcast, please use the following link: https://edge.media-server.com/mmc/p/zejeosdn

To participate in the call, please find details below:

Date:	Monday, March 8, 2021
Time:	0900 EST / 1400 GMT
Dial-in:	United Kingdom	[phone](Toll Free) / [phone] (Local)
	United States	[phone] (Toll Free) / [phone] (Local)
	All other locations	[phone]
Conference ID:	7268122

The press release and the live audio webcast will also be available in the investor section of Abcam’s corporate website at corporate.abcam.com/investors/reports-presentations/. An archive will be available after the call at that same address.

For further information, please contact:

Abcam
James Staveley, VP Investor Relations
[e-mail]
+ 44 (0) 1223 696 000

Numis - Nominated Adviser & Joint Corporate Broker
Garry Levin / Duncan Monteith / Huw Jeremy
+ 44 (0) 20 7260 1000

About Abcam plc
As an innovator in reagents and tools, Abcam's purpose is to serve life science researchers globally to achieve their mission, faster. Providing the research and clinical communities with tools and scientific support, the Company offers highly validated antibodies, assays and other research tools to address important targets in critical biological pathways.

Already a pioneer in data sharing and ecommerce in the life sciences, Abcam's ambition is to be the most influential company in life sciences by helping advance global understanding of biology and causes of disease, which, in turn, will drive new treatments and improved health.